These observations are consistent with pre-clinical studies in other cancer models showing STING-dependent upregulation of negative immune checkpoints and improved therapeutic responses when STING agonism is combined with immune checkpoint blockade (37, 52, 70). The gene discussed is STING1; the disease is cancer.